The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 07, 2025

Filed:

May. 21, 2019
Applicant:

Immunitybio, Inc., Culver City, CA (US);

Inventors:

Laurent H. Boissel, San Diego, CA (US);

Hans G. Klingemann, San Diego, CA (US);

Abhijit Dandapat, San Diego, CA (US);

Himani Chinnapen, San Diego, CA (US);

Assignee:

ImmunityBio, Inc., San Diego, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12N 5/16 (2006.01); A61K 38/17 (2006.01); A61K 38/20 (2006.01); A61K 39/395 (2006.01); A61K 40/15 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61K 40/46 (2025.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07K 14/54 (2006.01); C07K 14/55 (2006.01); C07K 14/705 (2006.01); C07K 14/735 (2006.01); C07K 16/28 (2006.01); C07K 16/32 (2006.01); C12N 5/0783 (2010.01); A61K 39/00 (2006.01); C07K 16/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/70535 (2013.01); A61K 38/1774 (2013.01); A61K 38/2013 (2013.01); A61K 38/2086 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 40/15 (2025.01); A61K 40/31 (2025.01); A61K 40/4203 (2025.01); A61K 40/4204 (2025.01); A61K 40/4205 (2025.01); A61K 40/421 (2025.01); A61K 40/4211 (2025.01); A61K 40/4215 (2025.01); A61K 40/4217 (2025.01); A61K 40/4221 (2025.01); A61K 40/4224 (2025.01); A61K 40/4249 (2025.01); A61K 40/4261 (2025.01); A61K 40/46 (2025.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 14/5443 (2013.01); C07K 14/55 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 16/2803 (2013.01); C07K 16/2827 (2013.01); C07K 16/2863 (2013.01); C07K 16/2866 (2013.01); C07K 16/2878 (2013.01); C07K 16/32 (2013.01); C12N 5/0646 (2013.01); A61K 2039/505 (2013.01); A61K 2239/22 (2023.05); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05); A61K 2239/49 (2023.05); A61K 2239/55 (2023.05); C07K 2317/53 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01); C12N 2510/00 (2013.01);
Abstract

Recombinant NK cells, and especially recombinant NK-92 cells express a chimeric antigen receptor (CAR) having an intracellular domain of FcεRIγ. Notably, CAR constructs with an intracellular domain of FcεRIγ had a substantially prolonged duration of expression and significantly extended cytotoxicity over time. The CAR may be expressed from RNA and DNA, preferably as a tricistronic construct that further encodes CD16 and a cytokine to confer autocrine growth support. Advantageously, such constructs also enable high levels of transfection and expression of the recombinant proteins and provide a convenient selection marker to facilitate rapid production of recombinant NK/NK-92 cells.


Find Patent Forward Citations

Loading…